Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

272 Views

047. COVID-19: Treatment: Thursday, 12:15 - 1:30 p.m.

Poster Session: COVID-19: Treatment

(529) Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study

Thursday, October 12, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

HM

Hugh Montgomery, MD

University College London
London, England, United Kingdom
FP

Francisco Padilla, MD

Centro de Investigación en Cardiología y Metabolismo
Guadalajara, Jalisco, Mexico
Jesus Abraham Simón Campos, MD

DIRECTOR
Köhler & Milstein Research/Hospital Agustín O’Horán
Mérida, Yucatan, Mexico
DA

Douglas Arbetter, MPH

AstraZeneca
Waltham, Massachusetts, United States
SS

Seth Seegobin, PhD

AstraZeneca
Cambridge, England, United Kingdom
AK

Alexandre Kiazand, MD

AstraZeneca
Gaithersburg, Maryland, United States
Katie Streicher, PhD (she/her/hers)

Head of Translational Medicine, Vaccines and Immune Therapies
AstraZeneca
Gaithersburg, Maryland, United States
NM

Nuria Martinez-Alier, PhD

AstraZeneca
Cambridge, England, United Kingdom

Taylor Cohen, PhD

Global Project Lead
AstraZeneca
Gaithersburg, Maryland, United States

Mark T. Esser, PhD

Phylogenetic and alpha toxin variant analyses of Staphylococcus aureus strains isolated from patient
AstraZeneca
Gaithersburg, Maryland, United States